Insight into epigenetic modulation of SCLC response to DNA damaging agents was provided by the discovery of epigenetic silencing of SLFN11 by EZH2 in the course of cisplatin-etoposide therapy, which may lead to treatment resistance or chemo-sensitive relapse [23]. This evidence concerns the gene EZH2 and small cell lung carcinoma.